P2.04-28 Use of Immune Checkpoint Inhibitors (ICIs) in Patients With Refractory Non-Small Cell Lung Cancer (NSCLC) and Poor Performance Status (PS)

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.1252
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Checkpoint Inhibitors in Squamous Non-Small Cell Lung Cancer (NSCLC)

Open Access Journal of Oncology and Medicine
2018English

Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer

Cancer
Cancer ResearchOncology
2017English

MA08.09 Impact of Brain Metastases in Immune Checkpoint Inhibitors (ICI) Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

High Mortality and Poor Treatment Efficacy of Immune Checkpoint Inhibitors in Patients With Severe Grade Checkpoint Inhibitor Pneumonitis in Non‐small Cell Lung Cancer

Thoracic Cancer
MedicinePulmonaryRespiratory MedicineOncology
2019English

P2.04-29 Preliminary Results With Tislelizumab in Chinese Patients With Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Receiving Concurrent Metformin and Immune Checkpoint Inhibitors

Lung Cancer Management
2019English

Immune-Checkpoint Inhibitor Treatment of Non-Small Cell Lung Cancer Patients

Jurnal Respirasi
2020English

When to Consider Immune Checkpoint Inhibitors in Oncogene-Driven Non-Small Cell Lung Cancer?

Current Treatment Options in Oncology
OncologyPharmacology
2019English

P3.03-28 LKB1 Mutation Status Is Associated With Poor Radiation Outcome in Patients With Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy